Development, Optimization, and Validation of Novel Anti-Tem1/Cd248 Affinity Agent for Optical Imaging in Cancer

Oncotarget - United States
doi 10.18632/oncotarget.2188
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Synthesis and Preclinical Validation of Novel P2Y1 Receptor Ligands as a Potent Anti-Prostate Cancer Agent

Scientific Reports
Multidisciplinary
2019English

Salinomycin: A Novel Anti-Cancer Agent With Known Anti-Coccidial Activities

Current Medicinal Chemistry
Organic ChemistryBiochemistryDrug DiscoveryMolecular MedicinePharmacology
2013English

Largazole as a Novel and Selective Anti-Breast Cancer Agent

2011English

Development of a Novel Anti-Hif-1α Screening System Coupled With Biochemical and Biological Validation for Rapidly Selecting Potent Anti-Cancer Compounds

Journal of Cancer
Oncology
2014English

Improved Oral Bioavailability in Rats of SR13668, a Novel Anti-Cancer Agent

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

Detection and Delineation of Oral Cancer With a PARP1 Targeted Optical Imaging Agent

Scientific Reports
Multidisciplinary
2016English

A Novel Multimodal Optical Imaging System for Early Detection of Oral Cancer

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Nuclear MedicineRadiologyOral SurgeryImagingDentistryForensic MedicinePathologySurgery
2016English

Myelin-Targeted, Texaphyrin-Based Multimodal Imaging Agent for Magnetic Resonance and Optical Imaging

Contrast Media and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2016English

CD248: A Therapeutic Target in Cancer and Fibrotic Diseases

Oncotarget
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy